Following Alain Wagner's belief that breakthrough research translates into entrepreneurial opportunities and that researcher's duty is to exploit these opportunities, at BFC we have been closely involved in the creation of five start ups. 
Single cell secretion-based sorting by droplet microfluidic; MicroOmix has developed a unique technology enabling to transform microfluidic droplet's surface into a highly sensitive sensor. This allows for the detection, at the single cell level, of secreted biomarkers entrapped within the droplet.
On the basis of the resulting distinctive signal it becomes possible to sort single cells according to their secretory profile, with a high accuracy and high throughput. The purified live cell sub-populations can be recovered by triggering droplet coalescence. This technology is currently applied to the screening for antibody secreting hybridomas.

MicroOmix SAS

Creation: April 2021
Syndivia is a biotechnology company that provides best-in-class bioconjugation technologies for the development of Antibody-Drug Conjugates. Our portfolio includes four unparalleled bioconjugation technologies within the two large domains of bioselective and bioorthogonal chemistry.

Syndivia SAS

Creation: March 2014
Syndivia is committed to the development of innovative linker technologies that enhance the performance of Antibody-Drug Conjugates by increasing their plasma stability and specificity of drug release. Syndivia exploits four patented bioconjugation technologies. Its management includes seasoned entrepreuneur backed by a strong team of dedicated professionals.

e-Novalys SAS

Creation: January 2009
e-Novalys is a chemo-informatics company that develops knowledge extraction tools and web 2.0 data sharing platforms for organic chemists. It proposes advanced search engine and predictive tools to find reaction conditions to perform chemical transformations.
This electronic working environment provides chemists with up to a 70% gain in productivity and opens unique ways to discover novel reactions and synthetic pathways.
These technologies are accessible via an internet platform. They offer an integrated environment, which will connect the chemistry community and link them to the various interlocutors (suppliers of reagent, laboratory equipment manufacturers, publishers, scientific editors, etc.). 
e-Novalys aspires to become the reference IT provider in the field of the information regarding chemical reactions. Leading laboratories in France, Italy, Great Britain, US, Canada, Poland are using e-Novalys systems.
PhytoDia identifies and develops plant ingredients with high added value for nutraceutics and cosmetics. Thanks to its research teams, its unique network of academic collaborations and its state of the art laboratories, PhytoDia proposes a technological platform covering the pharmacognosy, the phytochemistry, in vitro and in vivo pharmacology and so brings successful solutions for the objectification of the plant extracts.
To date Phytodia has out-licensed two proprietary active ingredients OLEA and COROLEA to major cosmetic company in Europe and Japan. Its pipeline of future ingredients from its internal research comprises of sun protecting/anti-wrinkle and energy expenditure booster extracts.

Phytodia SAS

Creation: November 2007
Number of employees:  11
Number of licensed patents:  2
Novalix Pharma started as chemical technology based contract research organization. NVX exploited technologies for high throughput reaction discovery/optimization that enabled fast structural scouting and lead optimization. Over time, the company has expanded its portfolio of technologies, in particular in the field of biophysic and label free molecules screening through acquisition of other companies.

Novalyst Discovery SAS

To date Novalix-Pharma 
Following the merging with Alix
To date NovAlix is offering unique technology platforms, such as HTS SPR fragment based hit finding, non-covalent MS screening, MS based rapid chemical optimization, medicinal chemistry expertise and process development.
Novalix pharma has research facilities located in France and in Spain. It employs 120 peoples among which 45 have PhDs. Its client base spans from large pharma to small biotech in USA, Japan and Europe.